<DOC>
	<DOCNO>NCT03045666</DOCNO>
	<brief_summary>48 patient , age 18 , pulmonary arterial hypertension ( PAH ) classify WHO III-IV , stable Macitentan therapy ( medication treat PAH patient ) , recruit study pulmonary hypertension ( PH ) clinic Soroka Medical Center . The patient randomly divide intervention group , exercise twice week 12 week , supervised physiotherapist , control group , receive medication . Tests perform begin intervention program , 6 week begin , end 12 week program , 3 month finish program .</brief_summary>
	<brief_title>Impact Rehabilitation Program PAH Patients Treated With Macitentan .</brief_title>
	<detailed_description>48 patient , age 18 , PAH classify WHO III-IV , stable Macitentan therapy , recruit study PH clinic Soroka Medical Center . The patient randomly divide intervention control group . The intervention group exercise pulmonary rehabilitation program twice week , 12 week . The exercise protocol include circuit training , 2-3 minute exercise interval , include aerobic strength training , supervised physiotherapist . The control group continue receive usual Macitentan treatment . All study participant undergo test begin intervention program , 6 week begin , end 12 week program , 3 month finish program . The test include cardio-pulmonary exercise test , 6 minute walk distance measurement , WHO functional class evaluation , level Brain natriuretic peptide ( BNP ) , EMPHASIS10 questionnaire ( emPHasis-10 questionnaire short questionnaire assess Health Related Quality Life pulmonary arterial hypertension ) , Short Form-36 ( SF-36 ) quality life questionnaire echocardiography . Once data collection complete , two way ANOVA repeat measure use ass change outcome measure .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Macitentan</mesh_term>
	<criteria>1 . PAH patient group 1 2 . Patients Age &gt; 18 year , 3 . Patients WHO III 4 . Patients Macitentan treatment stable diseasetargeted medication least 2 month prior inclusion . 1 . Patients significant comorbidity Pulmonary venoocclusive disease ( PVOD ) pulmonary capillary haemangiomatosis , Malignancy , Recent myocardial infarction last 2 week . 2 . Patients PAH specific medication treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>